Avelas Biosciences Voted Innovator of the Year at Field Service Medical 2020
February 26, 2020
SAN DIEGO, February 26, 2020 – Avelas Biosciences, Inc., a clinical-stage oncology company developing AVB-620 for real-time cancer detection was voted Innovator of the Year as part of the MedTech Innovation Showcase at Field Service Medical 2020.
Hosted at Field Service Medical’s annual meeting in San Diego, CA, the MedTech Innovation Showcase featured 15-minute presentations from select early-stage companies developing breakthrough technologies with the potential to transform areas of patient care. The winner of the showcase was selected via live audience vote.
“We are honored to be recognized by senior leaders in the medical device industry as Innovator of the Year,” said Jay Lichter, Chairman, President and Chief Executive Officer of Avelas. “Field Service Medical is a terrific conference that brings together service and support leaders from across the industry who have a pulse on of some of the biggest challenges in today’s healthcare environment. We thank Field Service Medical for the opportunity to continue to raise awareness of the great work we’re doing at Avelas to improve the surgical outcomes for women with breast cancer.”
For more information on Field Service Medical, please visit the event’s website: https://fieldservicemd.wbresearch.com/
About Avelas Biosciences
Avelas Biosciences is a San Diego-based drug-device company focused on developing AVB-620, a novel drug-device combination product for use during cancer surgery. AVB-620 improves surgery by detecting cancer in real-time and has the potential to become part of standard-of-care treatment for a variety of cancer surgeries. AVB-620 has completed a Phase Ib clinical trial assessing safety, pharmacokinetics, and fluorescence properties using tissue image analysis. A Phase II clinical trial for AVB-620 in breast cancer is ongoing. Avelas was founded on technology from Roger Y. Tsien, Ph.D., co-winner of the 2008 Nobel Prize in chemistry.